Can biomarkers be used to improve diagnosis and prediction of metabolic syndrome in childhood cancer survivors? A systematic review.

Autor: Pluimakers VG; Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands., van Santen SS; Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands.; Department of Medicine, Endocrinology, Erasmus Medical Center, Rotterdam, Netherlands., Fiocco M; Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands.; Medical Statistics, Department of Biomedical Data Science, Leiden UMC, Leiden, Netherlands.; Mathematical Institute, Leiden University, Leiden, Netherlands., Bakker ME; Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands.; Department of Medicine, University Medical Center Utrecht, Netherlands., van der Lelij AJ; Department of Medicine, Endocrinology, Erasmus Medical Center, Rotterdam, Netherlands., van den Heuvel-Eibrink MM; Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands., Neggers SJCMM; Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands.; Department of Medicine, Endocrinology, Erasmus Medical Center, Rotterdam, Netherlands.
Jazyk: angličtina
Zdroj: Obesity reviews : an official journal of the International Association for the Study of Obesity [Obes Rev] 2021 Nov; Vol. 22 (11), pp. e13312. Date of Electronic Publication: 2021 Jul 13.
DOI: 10.1111/obr.13312
Abstrakt: Childhood cancer survivors (CCS) are at increased risk to develop metabolic syndrome (MetS), diabetes, and cardiovascular disease. Common criteria underestimate adiposity and possibly underdiagnose MetS, particularly after abdominal radiotherapy. A systematic literature review and meta-analysis on the diagnostic and predictive value of nine newer MetS related biomarkers (adiponectin, leptin, uric acid, hsCRP, TNF-alpha, IL-1, IL-6, apolipoprotein B (apoB), and lipoprotein(a) [lp(a)]) in survivors and adult non-cancer survivors was performed by searching PubMed and Embase. Evidence was summarized with GRADE after risk of bias evaluation (QUADAS-2/QUIPS). Eligible studies on promising biomarkers were pooled. We identified 175 general population and five CCS studies. In the general population, valuable predictive biomarkers are uric acid, adiponectin, hsCRP and apoB (high level of evidence), and leptin (moderate level of evidence). Valuable diagnostic biomarkers are hsCRP, adiponectin, uric acid, and leptin (low, low, moderate, and high level of evidence, respectively). Meta-analysis showed OR for hyperuricemia of 2.94 (age-/sex-adjusted), OR per unit uric acid increase of 1.086 (unadjusted), and AUC for hsCRP of 0.71 (unadjusted). Uric acid, adiponectin, hsCRP, leptin, and apoB can be alternative biomarkers in the screening setting for MetS in survivors, to enhance early identification of those at high risk of subsequent complications.
(© 2021 The Authors. Obesity Reviews published by John Wiley & Sons Ltd on behalf of World Obesity Federation.)
Databáze: MEDLINE
Externí odkaz: